Enveda Biosciences, a Colorado-based biotechnology firm specializing in harnessing natural products and artificial intelligence for drug discovery in inflammation and immunology, has secured $150 million in Series D financing. Led by Premji Invest and supported by prominent investors including Kinnevik and Sanofi, the funding will drive clinical advancement of its lead candidate ENV-294 and underpin the expansion of over a dozen preclinical programs targeting diseases such as inflammatory bowel disease, fibrosis, and obesity. Enveda’s innovative platform leverages AI-guided natural molecule derivatives, offering a compelling approach to tackling complex multifactorial diseases.